Mesa Laboratories Reports 1% Revenue Increase to $60.1 Million for Quarter Ending June 30, 2026

Mesa Laboratories, Inc. reported a modest increase in revenue for the quarter ending June 30, 2026, achieving $60.1 million, up 1.0% from $59.5 million in the same period last year. The company’s gross profit also saw an increase, rising to $39.0 million from $36.9 million, reflecting a gross profit margin improvement of 2.9 percentage points to 64.9%. However, net income decreased by 40.3% to $2.8 million, compared to $4.7 million in the prior year, primarily due to increased non-operating expenses and a higher effective tax rate.

The financial performance was influenced by several operational changes. Notably, the company experienced a decrease in operating expenses, which fell by 5.6% to $32.0 million, largely due to reduced stock-based compensation and lower personnel costs. The operating income surged to $7.0 million, a significant increase from $3.1 million in the previous year, indicating improved operational efficiency. The company generated $14.7 million in cash from operating activities, a substantial increase from $1.9 million in the prior year, allowing for a reduction in outstanding debt by $8.7 million.

Mesa Laboratories operates through four reportable segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The Biopharmaceutical Development and Calibration Solutions segments reported revenue growth of 5.0% and 7.6%, respectively, driven by increased sales volumes and price adjustments. Conversely, the Sterilization and Disinfection Control segment saw a revenue decline of 3.6%, attributed to fulfillment challenges that affected customer shipment timing. The Clinical Genomics segment remained relatively flat, with revenue essentially unchanged from the previous year.

In terms of strategic developments, Mesa Laboratories continues to focus on organic growth through customer expansion and product innovation while also pursuing acquisitions to enhance its market position. The company reported a slight increase in its employee headcount, reflecting ongoing efforts to bolster its workforce in line with its growth strategy. As of June 30, 2026, Mesa Laboratories held $30.7 million in cash and cash equivalents, providing a solid liquidity position to support future investments and operational needs.

Looking ahead, Mesa Laboratories anticipates continued revenue growth driven by its strategic initiatives and operational efficiencies. The company remains committed to enhancing its product offerings and expanding its market reach, particularly in the Biopharmaceutical Development and Calibration Solutions segments. However, it acknowledges potential challenges from economic uncertainties and competitive pressures that may impact future performance.